Research
Hormonal
Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.
StrongSupportsVERY_HIGH confidence
The primary endpoint... Composite of adjudicated CV death or worsening HF events... HR 0.62 (0.41 to 0.95)... Change at 52 weeks in KCCQ-CSS... 6.9 (3.3 to 10.6)
Why this rating
Based on a randomized, placebo-controlled trial (SUMMIT) with clear statistical significance.
Source
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell et al. · Cardiovascular Diabetology · 2025
narrative_reviewCited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →